Abstract: Certain embodiments of the invention are directed to evaluating and identifying cells by recording and interpreting a time-dependent signal produced by unique cell respiration and permeability attributes of isolated viable cells.
Abstract: The present disclosure relates to non-natural NKG2D receptors attached to mammalian cell surfaces wherein the non-natural receptors do not directly signal or directly activate the cell when the receptor is bound by cognate non-natural ?1-?2 domains of NKG2D ligands modified to specifically bind the non-natural NKG2D receptors. The non-natural ?1-?2 domains of NKG2D ligands may be attached to heterologous atoms or molecules including polypeptides, in some embodiments cytokines or modified cytokines, antibodies or fragments of antibodies.
Type:
Grant
Filed:
November 5, 2019
Date of Patent:
April 16, 2024
Assignee:
XYPHOS BIOSCIENCES INC.
Inventors:
Kaman C. Kim, David W. Martin, Jr., Steven Williams
Abstract: A method for evaluating or monitoring metabolic effects of exercise or injury by detecting and/or quantifying microR-NAs in saliva. Compositions and methods of treatment based on detection of microRNAs.
Type:
Grant
Filed:
February 27, 2019
Date of Patent:
April 16, 2024
Assignees:
QUADRANT BIOSCIENCES INC., PENN STATE RESEARCH FOUNDATION, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Inventors:
Richard Uhlig, Steven D. Hicks, Frank A. Middleton
Abstract: Disclosed herein are salts and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane, including salts, solid forms of the compound and salts thereof, as well as polymorphs of solid forms. The solid forms disclosed herein may have improved properties, such as improved physical, chemical, and/or pharmacokinetic properties. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The disclosed salt and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane may be useful for treating neurological disease and/or a psychiatric disorder in a subject.
Abstract: Provided herein is the identification of markers and genes associated with powdery mildew susceptibility and resistance in Cannabis. The markers are useful for breeding Cannabis plants having resistance to powdery mildew, and methods for selecting plants by obtaining nucleic acids and detecting one or more markers that indicate resistance to powdery mildew to establish plant lines having such resistance are provided.
Abstract: The present invention relates to a novel benzotriazole derivative compound, a tautomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a stereoisomer thereof, which are related to a compound for inhibiting ENPP1, a composition for inhibiting ENPP1, and a method for inhibiting ENPP1.
Type:
Application
Filed:
January 28, 2022
Publication date:
April 11, 2024
Applicant:
TXINNO BIOSCIENCE INC.
Inventors:
Chan Sun Park, Sung Joon Kim, Ali Imran, Yoo Jin Na, So Ra Paik, Jung Hwan Choi, Sun Woo Lee, Yong Yea Park, Ah Ran Yu, Sun Young Park
Abstract: The invention provides systems and methods for making sequencing libraries that are useful for quantitatively analyzing nucleic acids in a sample. Sample nucleic acids are randomly cleaved at, and PCR handled are attached to, a random cut site. The nucleic acid is amplified into a sequencing library in which a sequencing primer generates a sequence read from adjacent the random cut site. The sequence reads can be mapped to a reference, but they will also include a unique identifier sequence that comes from within the nucleic acid molecule being analyzed, i.e., an intrinsic molecular identifier (IMI). The IMI is unique for each molecule and can thus be used to deduplicate sequence reads originating from the same molecule.
Abstract: Provided herein are compositions and methods for the multiplexed profiling of RNA and DNA modifications across transcriptomes and genomes, respectively. The methods combine molecular recognition of non-canonical features (e.g., base modifications, backbone modifications, lesions, and/or structural elements) of a target nucleic acid with a step of writing the information from this recognition event into the neighboring genetic sequence of the target nucleic acid using a barcode. The resultant barcoded nucleic acids are then converted into sequencing libraries and read by DNA/RNA sequencing methods. This step reveals the sequence of the barcode, which is correlated with the non-canonical feature in the target nucleic acid(s). The high throughput profiling methods described herein allow for localization of one or more modifications in a target nucleic acid. The methods also allow for identification of the nature and location of several or all DNA/RNA modifications in parallel.
Abstract: The present invention includes systems, methods and compositions for the in vivo bioconversion of water-soluble cannabinoids in plant cell suspension cultures.
Type:
Grant
Filed:
May 30, 2019
Date of Patent:
April 2, 2024
Assignee:
TRAIT BIOSCIENCES, INC.
Inventors:
Richard T. Sayre, Elton Carvalho Gonçalves, Tawanda Zidenga, Stephanie Willette
Abstract: Disclosed are conjugate molecules formed from an active agent which is linked to a cannabinoid moiety through a specified linker having ester and amide end groups. The active agent can be a COX-2 inhibitor moiety, and the cannabinoid moiety can be a cannabidiol moiety. These conjugate molecules are contemplated to potentially be effective in the treatment of medical conditions.
Type:
Grant
Filed:
April 21, 2023
Date of Patent:
April 2, 2024
Assignee:
AKOS BIOSCIENCES, INC.
Inventors:
Paul M. Hershberger, Yinghui Liu, Kirk William Hering, James Bernard Kramer, Ramanathan S. Lalgudi
Abstract: The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within the human PCSK9 gene. The present invention also encompasses methods for using such engineered meganucleases in a pharmaceutical composition and in methods for treating or reducing the symptoms of cholesterol-related disorders, such as hypercholesterolemia. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating cholesterol-related disorders, such as hypercholesterolemia.
Type:
Application
Filed:
May 4, 2023
Publication date:
March 28, 2024
Applicant:
Precision Biosciences, Inc.
Inventors:
Victor Bartsevich, Derek Jantz, James Jefferson Smith
Abstract: The present disclosure relates to recombinant polypeptides that have olivetolic acid cyclase activity, nucleic acids encoding these recombinant polypeptides, recombinant host cells that produce these recombinant polypeptides, and compositions comprising the recombinant polypeptides, nucleic acids, and/or recombinant host cells. The present disclosure also relates to uses of these recombinant polypeptides, nucleic acids encoding them, and recombinant host cells comprising them, in methods for the preparation of cannabinoids and cannabinoid precursors.
Type:
Application
Filed:
June 20, 2023
Publication date:
March 28, 2024
Applicants:
WILLOW BIOSCIENCES, INC., EPIMERON USA, INC.
Inventors:
Trish CHOUDHARY, Xueyang FENG, Thanh NGUYEN, Matthew WORKENTINE
Abstract: Provided herein are methods and compositions for treating and/or preventing hepatic encephalopathy involving administering to a subject a pharmaceutical composition comprising a purified bacterial mixture.
Abstract: The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within the human PCSK9 gene. The present invention also encompasses methods for using such engineered meganucleases in a pharmaceutical composition and in methods for treating or reducing the symptoms of cholesterol-related disorders, such as hypercholesterolemia. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating cholesterol-related disorders, such as hypercholesterolemia.
Type:
Application
Filed:
May 4, 2023
Publication date:
March 28, 2024
Applicant:
Precision Biosciences, Inc.
Inventors:
Victor Bartsevich, Derek Jantz, James Jefferson Smith
Abstract: A method and apparatus for preventing condensation on a cell culture plate transferred from an incubator to an imager. A block having a higher thermal conductivity layer and a lower thermal conductivity layer is preheated in an incubator. The block is placed on a cell culture plate either before or immediately after removing the cell culture plate from an incubator with the higher thermal conductivity layer resting on the plate and configured to overlie all of the wells of the plate. The culture plate is transported to an imager with the thermal block in place and the block is removed before inserting the culture plate into the imager.
Abstract: A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cash which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity. The Cascade complex with additional activity is combined with an RNA molecule to produce a ribonucleoprotein complex. The RNA molecule is selected to have substantial complementarity to a target sequence. Targeted ribonucleoproteins can be used as genetic engineering tools for precise cutting of nucleic acids in homologous recombination, non-homologous end joining, gene modification, gene integration, mutation repair or for their visualisation, transcriptional activation or repression.
Type:
Grant
Filed:
February 18, 2021
Date of Patent:
March 26, 2024
Assignee:
Caribou Biosciences, Inc.
Inventors:
Stan Johan Jozef Brouns, John van der Oost
Abstract: A plaque detection method and apparatus wherein at least one processor is programmed to receive above focus images to detect the presence of live cells without detecting the lysed cell materials, receive below focus images wherein virtual dark regions exist which are similar to cell shadows as seeds in a segmentation process and use contours around each resulting shape to obtain a subset that are more likely to be part of the cell population to define a cell map. A distance map is created in which each pixel value is the distance of that pixel from the nearest pixel of the cell map and the distance map is thresholded to create a first image of the places which are relatively far from the cells a second image with a smaller distance threshold to get an image that mimics the edges of the cells.
Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.
Type:
Application
Filed:
October 23, 2023
Publication date:
March 21, 2024
Applicant:
Aulos Bioscience, Inc
Inventors:
Inbar AMIT, Itay LEVIN, Guy NIMROD, Sharon FISCHMAN, Reut BARAK FUCHS, Marek STRAJBL, Timothy WYANT, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Yehezkel SASSON, Noam GROSSMAN, Natalia LEVITIN, Yanay OFRAN
Abstract: Provided herein are processes for manufacturing recombinant ranibizumab or a ranibizumab variant that include providing a liquid comprising recombinant ranibizumab or a ranibizumab variant that is substantially free of cells; capturing the recombinant ranibizumab or the ranibizumab variant in the liquid using an affinity chromatography column, wherein the eluate of the affinity chromatography column comprises the recombinant ranibizumab or the ranibizumab variant; purifying the recombinant ranibizumab or the ranibizumab variant in the eluate of step (b) using a first cation exchange chromatography column and buffers that have a pH of about pH 5.5 to about 7.
Type:
Application
Filed:
October 9, 2020
Publication date:
March 21, 2024
Applicant:
Coherus Biosciences, Inc.
Inventors:
John Robert Ogez, Brian L. Williamson, Nessa Mary Noone Hawkins